Back

Impact of real-world off-label dose of apixaban on long-term clinical outcomes in heart failure patients with atrial fibrillation and end stage kidney disease

31 August 2025 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation management: from anticoagulation to SGLT2 inhibitors Oral Anticoagulation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Sung Il Im

kosin university gospel hospital, Pusan (Korea (Republic of))

2 More presentations in this session

Presentation thumbnail
Impact of cardiac damage on cardioversion success in patients with atrial fibrillation and heart failure with preserved ejection fraction
Doctor P. Wilke (Duesseldorf, DE)
Abstract Slides Video
Presentation thumbnail
Effect of glucagon-like peptide-1 receptor agonists on atrial fibrillation incidence: a systematic review and meta-analysis
Mr K. Banerjee (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation management: from anticoagulation to SGLT2 inhibitors

The Event

Event poster

ESC Congress 2025

31 August 2025 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of Real-world Off-label dose of Apixaban on long-term clinical outcomes in Atrial Fibrillation patients with Heart failure and Chronic Kidney Disease
thumbnail
Congress Presentation
Impact of real-world off-label dose of Apixaban on long-term clinical outcomes in patients with atrial fibrillation and chronic kidney disease
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources